RJFSA
AVTX icon

Raymond James Financial Services Advisors’s Avalo Therapeutics AVTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed -$74K – 2560
2017
Q4 		$74K Buy
+8
New +$34.5K ﹤0.01% 2406

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $445M AUM 31.98% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Raymond James Financial Services Advisors's AVTX Position: Q1 2018 in Review

Raymond James Financial Services Advisors sold out of Avalo Therapeutics (AVTX) in Q1 2018, closing a stake of 8 shares — an estimated $74K sold.

Raymond James Financial Services Advisors first reported a position in AVTX in Q4 2017 and held it in 1 quarter. The position peaked at $74K in Q4 2017. 18 funds tracked by Wall St. Rank hold AVTX as of Q1 2018.

  • Raymond James Financial Services Advisors reported no remaining Avalo Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 8 Avalo Therapeutics shares in Q1 2018, an estimated $74K.
  • Raymond James Financial Services Advisors first reported a position in Avalo Therapeutics in Q4 2017 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Avalo Therapeutics position peaked at $74K in Q4 2017.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2018, filed 16 Apr 2018.